Press Release Archive

Johnson & Johnson to Participate in Goldman Sachs 43^rd Annual Global Healthcare Conference

Johnson & Johnson to Participate in Goldman Sachs 43^rd Annual Global Healthcare Conference

Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

The Company has also appointed Paul Ruh as CFO Designate

Mongon and Ruh to Assume New Leadership Roles Upon the Completion

of the Planned Separation of the Consumer Health Business

Planned Separation Expected to Occur in 2023

MEDIA STATEMENT May 09, 2022

Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus

Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus

Janssen continues to prioritize hepatitis B research, with the aim to bring forward an optimal combination treatment regimen

Collaborations between Janssen and Bavarian Nordic in HIV and Ebola continue

MEDIA STATEMENT May 05, 2022

Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet

Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet

Innovation May 05, 2022

MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia

May 02, 2022

Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference

Innovation April 25, 2022

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)

The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge

The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health challenges

The collaboration between Johnson & Johnson and H3D will help to further expand and strengthen Africa’s scientific capacity as a global hub for discovery research

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

Media Statement April 19, 2022

Johnson & Johnson Statement on Alabama Opioid Settlement Agreement

Johnson & Johnson Statement on Alabama Opioid Settlement Agreement

Financial April 19, 2022

Johnson & Johnson Reports Q1 2022 Results

Johnson & Johnson Reports Q1 2022 Results

Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%*

Earnings per share of $1.93 decreasing 16.8% and adjusted earnings per share of $2.67 increasing 3.1%*

Company maintaining 2022 full-year guidance for adjusted operational earnings per share and base business operational sales

Given global supply surplus and demand uncertainty, the Company is suspending COVID-19 Vaccine sales guidance, with no impact to adjusted operational earnings per share guidance

Internet Explorer is no longer supported by this website.

Topic

Date